A study (118) found that REV-ERBα, upon co-localization with MEF2a and MEF2c, could specifically inhibit MEF2a/MEF2c-driven cardiac hypertrophy and the aberrant activation of gene programs in HF, thereby playing a critical role in preventing ventricular remodeling. The gene discussed is MEF2C; the disease is cardiac hypertrophy.